Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO™, the company’s bivalent Respiratory Syncytial Virus (RSV) prefusion F (RSVpreF) vaccine. This FDA approval on May 31, 2023, prevents lower respiratory... READ →
Precision Vaccinations
/ June 1st, 2023Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.